 |
|
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin
Clin Mol Hepatol. 2023;29(1):77-98. Published online 2022 Oct 13 DOI: https://doi.org/10.3350/cmh.2022.0237
|
|
Citations to this article as recorded by
 Neuregulin 4 as a novel adipokine in energy metabolism
Yuanbin Liu, Mingkai Chen
Frontiers in Physiology.2023;[Epub] CrossRef Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne
Clinical and Molecular Hepatology.2023; 29(Suppl): S157. CrossRef Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
Seogsong Jeong, Woo-Young Shin, Yun Hwan Oh
Frontiers in Endocrinology.2023;[Epub] CrossRef A Combination of an Angiotensin II Receptor and a Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation
Junya Suzuki, Kosuke Kaji, Norihisa Nishimura, Takahiro Kubo, Fumimasa Tomooka, Akihiko Shibamoto, Satoshi Iwai, Yuki Tsuji, Yukihisa Fujinaga, Koh Kitagawa, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji
Biomedicines.2023; 11(5): 1295. CrossRef In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations
Young-Sun Lee, Ekihiro Seki
Cellular and Molecular Gastroenterology and Hepatology.2023; 16(3): 355. CrossRef Hypertension and NAFLD risk: Insights from the NHANES 2017–2018 and Mendelian randomization analyses
Mengqin Yuan, Jian He, Xue Hu, Lichao Yao, Ping Chen, Zheng Wang, Pingji Liu, Zhiyu Xiong, Yingan Jiang, Lanjuan Li
Chinese Medical Journal.2023;[Epub] CrossRef Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
Lucy Petagine, Mohammed Gulrez Zariwala, Vinood B Patel
World Journal of Gastroenterology.2023; 29(32): 4831. CrossRef
|